Published in Mol Pharmacol on February 01, 1986
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential. J Med Chem (1992) 2.01
[3H]xanthine amine congener of 1,3-dipropyl-8-phenylxanthine: an antagonist radioligand for adenosine receptors. Proc Natl Acad Sci U S A (1986) 1.85
Molecular probes for extracellular adenosine receptors. Biochem Pharmacol (1987) 1.47
Apparent affinity of some 8-phenyl-substituted xanthines at adenosine receptors in guinea-pig aorta and atria. Br J Pharmacol (1987) 1.45
A new high affinity, iodinated adenosine receptor antagonist as a radioligand/photoaffinity crosslinking probe. Mol Pharmacol (1987) 1.42
Species differences in structure-activity relationships of adenosine agonists and xanthine antagonists at brain A1 adenosine receptors. FEBS Lett (1986) 1.42
A [3H]amine congener of 1,3-dipropyl-8-phenylxanthine. A new radioligand for A2 adenosine receptors of human platelets. FEBS Lett (1986) 1.16
Functionalized congener approach to the design of ligands for G protein-coupled receptors (GPCRs). Bioconjug Chem (2009) 1.15
8-Substituted xanthines as antagonists at A1- and A2-adenosine receptors. Biochem Pharmacol (1988) 1.10
A novel pharmacological approach to treating cardiac ischemia. Binary conjugates of A1 and A3 adenosine receptor agonists. J Biol Chem (2000) 1.06
Xanthines as adenosine receptor antagonists. Handb Exp Pharmacol (2011) 0.96
Sulfur-containing 1,3-dialkylxanthine derivatives as selective antagonists at A1-adenosine receptors. J Med Chem (1989) 0.93
Rapid identification of improved protein ligands using peptoid microarrays. Bioorg Med Chem Lett (2009) 0.90
Xanthine functionalized congeners as potent ligands at A2-adenosine receptors. J Med Chem (1987) 0.89
Structure-activity relationships of 1,3-dialkylxanthine derivatives at rat A3 adenosine receptors. J Med Chem (1994) 0.86
Adenosine receptor prodrugs: towards kidney-selective dialkylxanthines. J Pharmacol Exp Ther (1989) 0.86
XAC, a functionalized congener of 1,3-dialkylxanthine, antagonizes A1 adenosine receptor-mediated inhibition of renin secretion in vitro. Arch Int Pharmacodyn Ther (1987) 0.86
Adenosine analogs with covalently attached lipids have enhanced potency at A1-adenosine receptors. FEBS Lett (1987) 0.85
Binary drugs: conjugates of purines and a peptide that bind to both adenosine and substance P receptors. J Med Chem (1987) 0.82
Adenosine in heart and lung disease. Proceedings of the first Cardiothoracic Institute Workshop. 30 March 1988, London. Abstracts. Postgrad Med J (1988) 0.75
[A new method for synthesis of peptides: activation of the carboxyl group with dicyclohexylcarbodiimide using 1-hydroxybenzotriazoles as additives]. Chem Ber (1970) 3.77
Adenosine receptors: targets for future drugs. J Med Chem (1982) 3.44
Functionalized congeners of 1,3-dialkylxanthines: preparation of analogues with high affinity for adenosine receptors. J Med Chem (1985) 2.52
Functionalized congeners of adenosine: preparation of analogues with high affinity for A1-adenosine receptors. J Med Chem (1985) 2.12
Subclasses of adenosine receptors in the central nervous system: interaction with caffeine and related methylxanthines. Cell Mol Neurobiol (1983) 2.04
1,3-Dialkyl-8-(p-sulfophenyl)xanthines: potent water-soluble antagonists for A1- and A2-adenosine receptors. J Med Chem (1985) 1.87
Adenosine receptor binding: structure-activity analysis generates extremely potent xanthine antagonists. Proc Natl Acad Sci U S A (1983) 1.68
Probing the adenosine receptor with adenosine and xanthine biotin conjugates. FEBS Lett (1985) 1.52
[Di-tert.-butyl-dicarbonate, a useful tert.-Butyloxycardonylating reagent (author's transl)]. Hoppe Seylers Z Physiol Chem (1976) 1.48
4-(3-Cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone (ZK 62711): a potent inhibitor of adenosine cyclic 3',5'-monophosphate phosphodiesterases in homogenates and tissue slices from rat brain. Mol Pharmacol (1976) 1.46
Adenosine receptors. Adv Cyclic Nucleotide Protein Phosphorylation Res (1985) 1.45
Conjugates of catecholamines. 1. N-alkyl-functionalized carboxylic acid congeners and amides related to isoproterenol. J Med Chem (1983) 1.20
On the mechanism of action of theophylline and caffeine. Acta Med Scand (1985) 1.18
A novel 8-phenyl-substituted xanthine derivative is a selective antagonist at adenosine A1-receptors in vivo. Acta Physiol Scand (1985) 1.16
Adenosine antagonism and related effects of theophylline derivatives in guinea pig ileum longitudinal muscle. Acta Physiol Scand (1984) 1.08
A1 and A2 adenosine receptor activation inhibits and stimulates renin secretion of rat renal cortical slices. J Pharmacol Exp Ther (1985) 1.08
Adenosine receptors mediating inhibitory electrophysiological responses in rat hippocampus are different from receptors mediating cyclic AMP accumulation. Naunyn Schmiedebergs Arch Pharmacol (1984) 1.08
Conjugates of catecholamines. II. In vitro and in vivo pharmacological activity of N-alkyl-functionalized carboxylic acid congeners and amides related to isoproterenol. Mol Pharmacol (1983) 1.08
Some novel approaches to the design and synthesis of peptide-catecholamine conjugates. Biopolymers (1983) 1.02
The oxidative cleavage of tyrosyl-peptide bonds during iodination. Biochemistry (1969) 0.95
Conjugates of catecholamines. IV. In vitro and in vivo pharmacological activity of monodisperse oligopeptide conjugates. J Pharmacol Exp Ther (1983) 0.91
Conjugates of catecholamines. III. Synthesis and characterization of monodisperse oligopeptides conjugates related to isoproterenol. Int J Pept Protein Res (1983) 0.91
International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev (2001) 9.90
Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells. Proc Natl Acad Sci U S A (1981) 6.73
Nomenclature and classification of purinoceptors. Pharmacol Rev (1994) 5.32
Homobatrachotoxin in the genus Pitohui: chemical defense in birds? Science (1992) 4.73
Forskolin: a unique diterpene activator of cyclic AMP-generating systems. J Cyclic Nucleotide Res (1981) 4.05
Direct observation of brownian motion of lipids in a membrane. Proc Natl Acad Sci U S A (1991) 3.91
Diffusion of injected macromolecules within the cytoplasm of living cells. Proc Natl Acad Sci U S A (1981) 3.61
Hydroxylation-induced migration: the NIH shift. Recent experiments reveal an unexpected and general result of enzymatic hydroxylation of aromatic compounds. Science (1967) 3.60
Adenosine receptors: targets for future drugs. J Med Chem (1982) 3.44
Arene oxides: a new aspect of drug metabolism. Science (1974) 3.34
Cis-1,2-dihydroxy-1,2-dihydronaphthalene: a bacterial metabolite from naphthalene. Arch Biochem Biophys (1971) 3.31
Adenosine receptors in brain membranes: binding of N6-cyclohexyl[3H]adenosine and 1,3-diethyl-8-[3H]phenylxanthine. Proc Natl Acad Sci U S A (1980) 3.20
Alkylxanthines: inhibition of adenosine-elicited accumulation of cyclic AMP in brain slices and of brain phosphodiesterase activity. Life Sci (1979) 2.94
Forskolin: its biological and chemical properties. Adv Cyclic Nucleotide Protein Phosphorylation Res (1986) 2.68
Adenosine receptors and behavioral actions of methylxanthines. Proc Natl Acad Sci U S A (1981) 2.66
125I-4-aminobenzyl-5'-N-methylcarboxamidoadenosine, a high affinity radioligand for the rat A3 adenosine receptor. Mol Pharmacol (1994) 2.65
Adenosine receptors in the central nervous system: relationship to the central actions of methylxanthines. Life Sci (1981) 2.58
Functionalized congeners of 1,3-dialkylxanthines: preparation of analogues with high affinity for adenosine receptors. J Med Chem (1985) 2.52
Regulation of plasma membrane recycling by CFTR. Science (1992) 2.50
Structural mosaicism on the submicron scale in the plasma membrane. Biophys J (1998) 2.50
The Concise Guide to PHARMACOLOGY 2013/14: overview. Br J Pharmacol (2013) 2.48
Activation of adenylate cyclase by the diterpene forskolin does not require the guanine nucleotide regulatory protein. J Biol Chem (1981) 2.48
1,2-naphthalene oxide as an intermediate in the microsomal hydroxylation of naphthalene. Biochemistry (1970) 2.47
Unconfined lateral diffusion and an estimate of pericellular matrix viscosity revealed by measuring the mobility of gold-tagged lipids. J Cell Biol (1993) 2.47
Arene oxides and the NIH shift: the metabolism, toxicity and carcinogenicity of aromatic compounds. Experientia (1972) 2.45
Adenosine A3 receptor stimulation and cerebral ischemia. Eur J Pharmacol (1994) 2.33
A radioisotopic method for measuring the formation of adenosine 3',5'-cyclic monophosphate in incubated slices of brain. J Neurochem (1969) 2.13
Spatial Fourier analysis of video photobleaching measurements. Principles and optimization. Biophys J (1991) 2.13
Functionalized congeners of adenosine: preparation of analogues with high affinity for A1-adenosine receptors. J Med Chem (1985) 2.12
2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors. J Med Chem (1994) 2.10
CFTR chloride channel regulation by an interdomain interaction. Science (1999) 2.09
Towards a revised nomenclature for P1 and P2 receptors. Trends Pharmacol Sci (1997) 2.09
Batrachotoxin: chemistry and pharmacology. Science (1971) 2.09
Subclasses of adenosine receptors in the central nervous system: interaction with caffeine and related methylxanthines. Cell Mol Neurobiol (1983) 2.04
Quality control procedure for 6-[18F]fluoro-L-DOPA: a presynaptic PET imaging ligand for brain dopamine neurons. J Nucl Med (1989) 2.04
Biochemical characterization of a filtered synaptoneurosome preparation from guinea pig cerebral cortex: cyclic adenosine 3':5'-monophosphate-generating systems, receptors, and enzymes. J Neurosci (1985) 2.02
Regulation of CFTR chloride channels by syntaxin and Munc18 isoforms. Nature (1997) 1.98
Site-directed mutagenesis identifies residues involved in ligand recognition in the human A2a adenosine receptor. J Biol Chem (1995) 1.92
Toxicity of Panamanian poison frogs (Dendrobates): some biological and chemical aspects. Science (1967) 1.88
A binding site model and structure-activity relationships for the rat A3 adenosine receptor. Mol Pharmacol (1994) 1.87
1,3-Dialkyl-8-(p-sulfophenyl)xanthines: potent water-soluble antagonists for A1- and A2-adenosine receptors. J Med Chem (1985) 1.87
[3H]xanthine amine congener of 1,3-dipropyl-8-phenylxanthine: an antagonist radioligand for adenosine receptors. Proc Natl Acad Sci U S A (1986) 1.85
Synthesis, biological activity, and molecular modeling of ribose-modified deoxyadenosine bisphosphate analogues as P2Y(1) receptor ligands. J Med Chem (2000) 1.85
Identification of potent, selective P2Y-purinoceptor agonists: structure-activity relationships for 2-thioether derivatives of adenosine 5'-triphosphate. J Med Chem (1993) 1.84
Competitive and selective antagonism of P2Y1 receptors by N6-methyl 2'-deoxyadenosine 3',5'-bisphosphate. Br J Pharmacol (1998) 1.80
Differential effects of P2-purinoceptor antagonists on phospholipase C- and adenylyl cyclase-coupled P2Y-purinoceptors. Br J Pharmacol (1994) 1.77
Adenosine receptor binding: structure-activity analysis generates extremely potent xanthine antagonists. Proc Natl Acad Sci U S A (1983) 1.68
Role of the extracellular loops of G protein-coupled receptors in ligand recognition: a molecular modeling study of the human P2Y1 receptor. Biochemistry (1999) 1.64
A mutational analysis of residues essential for ligand recognition at the human P2Y1 receptor. Mol Pharmacol (1997) 1.63
A physiological role of the adenosine A3 receptor: sustained cardioprotection. Proc Natl Acad Sci U S A (1998) 1.63
Adenosine A1 and A2 receptors: structure--function relationships. Med Res Rev (1992) 1.62
Alkaloids from dendrobatid frogs: structures of two omega-hydroxy congeners of 3-butyl-5-propylindolizidine and occurrence of 2,5-disubstituted pyrrolidines and a 2,6-disubstituted piperidine. J Nat Prod (1986) 1.61
Deoxyadenosine bisphosphate derivatives as potent antagonists at P2Y1 receptors. J Med Chem (1998) 1.61
Human P2Y1 receptor: molecular modeling and site-directed mutagenesis as tools to identify agonist and antagonist recognition sites. J Med Chem (1998) 1.61
The role of arene oxide-oxepin systems in the metabolism of aromatic substrates. 3. Formation of 1,2-naphthalene oxide from naphthalene by liver microsomes. J Am Chem Soc (1968) 1.58
A2A adenosine receptors from rat striatum and rat pheochromocytoma PC12 cells: characterization with radioligand binding and by activation of adenylate cyclase. Mol Pharmacol (1992) 1.57
Direct preconditioning of cultured chick ventricular myocytes. Novel functions of cardiac adenosine A2a and A3 receptors. J Clin Invest (1996) 1.57
Perhydrohistrionicotoxin: a potential ligand for the ion conductance modulator of the acetylcholine receptor. Proc Natl Acad Sci U S A (1977) 1.55
Glutamate residues in the second extracellular loop of the human A2a adenosine receptor are required for ligand recognition. Mol Pharmacol (1996) 1.54
The role of amino acids in extracellular loops of the human P2Y1 receptor in surface expression and activation processes. J Biol Chem (1999) 1.54
A new class of tyrosine hydroxylase inhibitors and a simple assay of inhibition in vivo. Biochem Pharmacol (1967) 1.54
Probing the adenosine receptor with adenosine and xanthine biotin conjugates. FEBS Lett (1985) 1.52
A role for central A3-adenosine receptors. Mediation of behavioral depressant effects. FEBS Lett (1993) 1.51
Mutagenesis reveals structure-activity parallels between human A2A adenosine receptors and biogenic amine G protein-coupled receptors. J Med Chem (1997) 1.51
Direct measurement of lateral transport in membranes by using time-resolved spatial photometry. Proc Natl Acad Sci U S A (1985) 1.51
Identification of the A2 adenosine receptor binding subunit by photoaffinity crosslinking. Proc Natl Acad Sci U S A (1989) 1.50
Binding of batrachotoxinin A 20-alpha-benzoate to a receptor site associated with sodium channels in synaptic nerve ending particles. J Biol Chem (1981) 1.48
8-(3-Chlorostyryl)caffeine (CSC) is a selective A2-adenosine antagonist in vitro and in vivo. FEBS Lett (1993) 1.47
Molecular probes for extracellular adenosine receptors. Biochem Pharmacol (1987) 1.47
Levels of batrachotoxin and lack of sensitivity to its action in poison-dart frogs (Phyllobates). Science (1980) 1.46
Histrionicotoxins: roentgen-ray analysis of the novel allenic and acetylenie spiroalkaloids isolated from a Colombian frog, Dendrobates histrionicus. Proc Natl Acad Sci U S A (1971) 1.46
Activation of cyclic AMP-generating systems in brain membranes and slices by the diterpene forskolin: augmentation of receptor-mediated responses. J Neurochem (1982) 1.46
4-(3-Cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone (ZK 62711): a potent inhibitor of adenosine cyclic 3',5'-monophosphate phosphodiesterases in homogenates and tissue slices from rat brain. Mol Pharmacol (1976) 1.46
Apparent affinity of some 8-phenyl-substituted xanthines at adenosine receptors in guinea-pig aorta and atria. Br J Pharmacol (1987) 1.45
Adenosine receptors. Adv Cyclic Nucleotide Protein Phosphorylation Res (1985) 1.45
Epibatidine, a potent analgetic and nicotinic agonist. Mol Pharmacol (1994) 1.44
Monooxygenase activity in Cunninghamella bainieri: evidence for a fungal system similar to liver microsomes. Arch Biochem Biophys (1973) 1.44
Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A(2B) adenosine receptors. J Med Chem (2000) 1.44
Distinct pathways of desensitization of A1- and A2-adenosine receptors in DDT1 MF-2 cells. Mol Pharmacol (1991) 1.42
A new high affinity, iodinated adenosine receptor antagonist as a radioligand/photoaffinity crosslinking probe. Mol Pharmacol (1987) 1.42
Species differences in structure-activity relationships of adenosine agonists and xanthine antagonists at brain A1 adenosine receptors. FEBS Lett (1986) 1.42